CalciMedica, Inc. (CALC)
| Market Cap | 12.86M -52.3% |
| Revenue (ttm) | n/a |
| Net Income | -19.54M |
| EPS | -1.27 |
| Shares Out | 15.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 311,458 |
| Open | 0.9190 |
| Previous Close | 0.8700 |
| Day's Range | 0.7549 - 0.9200 |
| 52-Week Range | 0.4606 - 7.2000 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 10.33 (+1,164.38%) |
| Earnings Date | May 12, 2026 |
About CALC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CALC stock is "Buy." The 12-month stock price target is $10.33, which is an increase of 1,164.38% from the latest price.
News
CalciMedica Quarterly report: Q1 2026
CalciMedica has published its Q1 2026 quarterly earnings report on May 12, 2026.
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480,...
CalciMedica price target lowered to $10 from $20 at Oppenheimer
Oppenheimer lowered the firm’s price target on CalciMedica (CALC) to $10 from $20 and keeps an Outperform rating on the shares. The firm notes CalciMedica reported updates to its programs…
CalciMedica files $125M mixed securities shelf
16:55 EST CalciMedica (CALC) files $125M mixed securities shelf
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivo...
CalciMedica Registration statement: Registration Filing
CalciMedica filed a registration statement on March 3, 2026, providing details about a securities offering with the SEC.
CalciMedica downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded CalciMedica (CALC) to Neutral from Buy without a price target The immediate discontinuation for the Phase 2 KOURAGE clinical trial in acute kidney injury removes a major…
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNe...
CalciMedica Registration statement: Registration Filing
CalciMedica filed a registration statement on November 13, 2025, providing details about a securities offering with the SEC.
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreati...
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with ex...
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of A...
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif. , Oct. 14, 2025 /PRNewswire/ --...
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
LA JOLLA, Calif. , Sept. 2, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium releas...
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pa...
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
LA JOLLA, Calif. , July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release...
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc analysis of patients in the Phase 2 CARDEA trial of Auxora in severe COV...
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
LA JOLLA, Calif. , June 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium releas...
CalciMedica Proxy statement: Proxy Filing
CalciMedica filed a proxy statement on June 9, 2025, providing details for shareholder voting and corporate governance matters.
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three recent medical meetings, includ...
CalciMedica Proxy statement: Proxy Filing
CalciMedica filed a proxy statement on April 30, 2025, providing details for shareholder voting and corporate governance matters.
CalciMedica Proxy statement: Proxy Filing
CalciMedica filed a proxy statement on April 29, 2025, providing details for shareholder voting and corporate governance matters.
CalciMedica Announces Presentations at Upcoming Medical Meetings
LA JOLLA, Calif. , April 17, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium relea...
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
LA JOLLA, Calif. , April 1, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium releas...
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in th...